A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevant ErbB-family dimers. Afatinib has demonstrated preclinical activity in human epidermal growth factor receptor HER2 (ErbB2)-positive and triple-negative xenograft models of breast cancer, and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuler, Martin, Awada, Ahmad, Harter, Philipp, Canon, Jean Luc, Possinger, Kurt, Schmidt, Marcus, De Grève, Jacques, Neven, Patrick, Dirix, Luc, Jonat, Walter, Beckmann, Matthias W., Schütte, Jochen, Fasching, Peter A., Gottschalk, Nina, Besse-Hammer, Tatiana, Fleischer, Frank, Wind, Sven, Uttenreuther-Fischer, Martina, Piccart, Martine, Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409367/
https://www.ncbi.nlm.nih.gov/pubmed/22763464
http://dx.doi.org/10.1007/s10549-012-2126-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409367/
https://www.ncbi.nlm.nih.gov/pubmed/22763464
http://dx.doi.org/10.1007/s10549-012-2126-1

Ejemplares similares